DENVER, July 24, 2007 (PRIME NEWSWIRE) -- Coram, Inc., a leading national provider of specialty home infusion and specialty pharmaceutical distribution services, has announced that it has become an approved provider of Soliris(tm) for Alexion Pharmaceuticals, Inc. Soliris is the first and only therapy approved for paroxysmal nocturnal hemoglobinuria, or PNH, a rare, disabling and life-threatening blood disorder characterized by chronic red blood cell destruction, otherwise known as hemolysis.
In clinical studies, patients who received Soliris had significant reductions in hemolysis. They also achieved improvements in anemia, less fatigue, better quality of life and fewer blood clots. Soliris is currently available through Coram's network of more than 70 branches and over 50 ambulatory infusion suites throughout the nation.
"We are pleased to add Soliris to the extensive list of treatments available through our network of pharmacies and infusion suites," said John J. Arlotta, Coram's Chairman and CEO. "Coram's 25-year history as a provider of specialty infusion services makes us the perfect choice for the administration of Soliris. Our ability to offer this therapy in both the home and infusion suite setting provides patients with a choice of safe, convenient environments in which to receive their treatment."
About Coram
Coram is a leading national provider of specialty home infusion and specialty pharmaceutical distribution services. With more than 70 full-service branch pharmacies and over 50 ambulatory infusion suites, the company offers both national presence and comprehensive local coverage. Coram's 25 years of experience, clinical expertise and commitment to positive outcomes has earned it a reputation for excellence among patients, clinicians and payors nationwide. The company is nationally accredited by the Accreditation Commission for Health Care, Inc. For more information about Coram, visit www.coramhc.com or call 1.800.CoramHC.
Soliris(tm) is a trademark of Alexion Pharmaceuticals, Inc. (www.alexionpharm.com). For more information about Soliris, visit www.soliris.net.